John Pinching is an Editor at RamaOnHealthcare and PharmaTimes Media Ltd. He covers a range of themes in medicine and healthcare, with a focus on pharmaceutical manufacturing, regulation, and advancements in oncology, immunotherapy, and gene therapy. John is featured in prominent publications, contributing to discussions on healthcare technology and workforce issues.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
John's coverage heavily focuses on healthcare and pharmaceutical industry, particularly press releases and data citations. He may prefer pitches with access to exclusive data or insights into the latest advancements in pharmaceuticals, medical treatments, clinical trials, mergers and acquisitions within the healthcare sector.
Given his extensive use of press releases as sources for his articles, he may be interested in receiving well-documented pitches with detailed information about newsworthy developments within the healthcare and pharmaceutical industries.
While John does not have a specific geographic focus mentioned, it is evident that his interest lies in global developments within the healthcare and pharmaceutical sectors. Therefore, he would likely appreciate relevant information from experts across different regions impacting these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Pinching
SEGRAM aims to offer an alternative to glucocorticoid‑based treatment
By: John Pinching
Early-stage study marks milestone for regenerative medicine
By: John Pinching
New option for adults with IPF and PPF
By: John Pinching
Roche therapy accepted for adults ineligible for stem cell transplant
By: John Pinching
Non-hormonal option to be made available for patients unsuitable for HRT
By: John Pinching
Breakwater data show significant survival gains over standard chemotherapy
Guidance expands treatment options for patients
B. Braun has appointed Sophie Spencer as Social Value & ESG Specialist
By: John Pinching
Partnership to support first‑in‑human trial of EPY201 in epilepsy
Latus Bio has appointed Bethany Mancilla as Chief Business Officer
